# Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma

> **NCT00829465** · PHASE4 · COMPLETED · sponsor: **Eastern Hepatobiliary Surgery Hospital** · enrollment: 400 (actual)

## Conditions studied

- Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** Licartin
- **PROCEDURE:** Transcatheter arterial chemoembolization

## Key facts

- **NCT ID:** NCT00829465
- **Lead sponsor:** Eastern Hepatobiliary Surgery Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-12
- **Final completion:** 2010-12
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2016-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00829465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00829465, "Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00829465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*